Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

Go back to Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

Agios Pharma (AGIO) Releases Initial AG-120 Data; Oppenheimer Reiterates Perform

November 9, 2015 9:28 AM EST

Oppenheimer reiterated a Perform rating on Agios Pharma (NASDAQ: AGIO) following initial data from an ongoing phase I trial of AG-120. AG-120 was generally well tolerated in advanced solid tumors including glioma, IHCC and chondrosarcoma, with no dose-limiting toxicities (DLTs) observed based on the... More